Behind the Sequence

At the recent American Association for the Advancement of Science meeting held in San Francisco, Celera Genomics CEO J. Craig Venter and National Human Genome Research Institute director Francis S. Collins spent considerable time appeasing autograph seekers at their respective plenary lectures--the former, signing dozens of copies of the February 16 issue of AAAS's journal Science, the latter, copies of the February 15 issue of Nature. They were the sorts of receptions usually experienced by roc

Written byEugene Russo
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

At the recent American Association for the Advancement of Science meeting held in San Francisco, Celera Genomics CEO J. Craig Venter and National Human Genome Research Institute director Francis S. Collins spent considerable time appeasing autograph seekers at their respective plenary lectures--the former, signing dozens of copies of the February 16 issue of AAAS's journal Science, the latter, copies of the February 15 issue of Nature. They were the sorts of receptions usually experienced by rock stars, not scientists. But, of course, these were no ordinary issues of Nature and Science.

The landmark human genome papers that appeared in mid-February-- published by rival research groups and, after months of arduous negotiations, by rival journals Nature and Science1-3--represent more than milestones of scientific achievement. They're also, in the words of University of Pennsylvania bioethicist Arthur Caplan, "case studies in how fundamentally values infuse science" in terms of how politics, competition, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies